Akero aims to develop and deliver transformational medicines to patients with high unmet medical need. Akeroâs current focus is advancing our lead program, AKR-001, to provide a powerful new therapy for patients with NASH (non-alcoholic steatohepatitis). Akero is led by industry veterans with decades of experience delivering innovative medicines to patients. We are united in our commitment to developing transformational new therapies for NASH and other serious metabolic diseases. Source
No articles found.
Luna (NASDAQ:LUNA) develops and manufactures new-generation products for the healt...
Luna (NASDAQ:LUNA) develops and manufactures ne...
Atreca is a biotechnology company developing novel therapeutics drawn from human i...
Atreca is a biotechnology company developing no...
Optinose is a specialty pharmaceutical company focused on creating and bringing to...
Optinose is a specialty pharmaceutical company ...
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...
Celgene Corporation, headquartered in Summit, N...
KalVista is a pharmaceutical company focused on the discovery, development and com...
KalVista is a pharmaceutical company focused on...
We are a clinical-stage biopharmaceutical company focused on improving the lives o...
We are a clinical-stage biopharmaceutical compa...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Join the National Investor Network and get the latest information with your interests in mind.